Scarica l'app Stockscreener
22.04
1.78%
-0.40
Pre-mercato:
22.11
0.07
+0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$22.44
Aprire:
$22.49
Volume 24 ore:
36.84M
Relative Volume:
0.81
Capitalizzazione di mercato:
$125.00B
Reddito:
$63.63B
Utile/perdita netta:
$8.03B
Rapporto P/E:
15.63
EPS:
1.41
Flusso di cassa netto:
$9.84B
1 W Prestazione:
-2.00%
1M Prestazione:
-14.31%
6M Prestazione:
-25.72%
1 anno Prestazione:
-14.21%
Intervallo 1D:
$21.95
$22.68
Intervallo di 1 settimana:
$21.09
$22.93
Portata 52W:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
22.04 | 125.00B | 63.63B | 8.03B | 9.84B | 1.41 |
|
LLY
Lilly Eli Co
|
734.90 | 660.07B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.91 | 344.63B | 89.33B | 21.81B | 18.06B | 8.99 |
|
ABBV
Abbvie Inc
|
171.68 | 303.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
62.88 | 279.13B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.58 | 216.43B | 51.72B | 11.94B | 13.81B | 5.88 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha
Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq
GSK, Pfizer Zantac Appeal Gets Tough Questions From Some Delaware Judges - Bloomberg.com
Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - MarketScreener
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire
Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha
What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq
Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com
Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com
Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace
Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com
Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance
Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView
Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha
Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research
Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com
Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India
TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail
BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged - Yahoo Finance
Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance
What You Need To Know Ahead Of Pfizer's Earnings Release - Barchart.com
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN
Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool
Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com
Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com
Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus
Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus
Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com
Pfizer Ends Development of Its Obesity Pill - Time Magazine
Pfizer ends development of potential pill obesity treatment - CNN
Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun
Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Health Care Up on Defensive DemandHealth Care Roundup - MarketScreener
Obesity Drug Developers Rise on M&A Hopes After Pfizer Setback - Bloomberg.com
Pfizer halts development of weight loss pill after liver injury report - KFXL
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our Valuation - Morningstar
Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg
Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review - Mega Doctor News
Pfizer ends development of weight-loss pill after patient's liver injury - upi.com
Thoracic Radiculopathy Market Is Booming Worldwide 2025-2032 | Pfizer Inc.,Johnson Johnson (DePuy Synthes) - openPR.com
Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure? - The Globe and Mail
Pfizer’s Danuglipron Is Done, Sparking M&A Speculation - insights.citeline.com
Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our $42 Valuation - Morningstar
PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener
Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):